Aligos Therapeutics Inc - Asset Resilience Ratio
Aligos Therapeutics Inc (ALGS) has an Asset Resilience Ratio of 38.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Aligos Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Aligos Therapeutics Inc's Asset Resilience Ratio has changed over time. See Aligos Therapeutics Inc (ALGS) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Aligos Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Aligos Therapeutics Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $24.93 Million | 38.61% |
| Total Liquid Assets | $24.93 Million | 38.61% |
Asset Resilience Insights
- Very High Liquidity: Aligos Therapeutics Inc maintains exceptional liquid asset reserves at 38.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aligos Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Aligos Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Aligos Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.25% | $59.54 Million | $88.53 Million | +38.80pp |
| 2024-12-31 | 28.45% | $19.94 Million | $70.09 Million | +28.50pp |
| 2023-12-31 | -0.05% | $-70.00K | $151.53 Million | -30.37pp |
| 2022-12-31 | 30.32% | $44.48 Million | $146.69 Million | +28.66pp |
| 2021-12-31 | 1.66% | $3.92 Million | $235.37 Million | -7.05pp |
| 2020-12-31 | 8.72% | $23.13 Million | $265.30 Million | -24.11pp |
| 2019-12-31 | 32.83% | $48.10 Million | $146.52 Million | -29.20pp |
| 2018-12-31 | 62.02% | $66.82 Million | $107.73 Million | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more